PASELLO, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.375
EU - Europa 804
AS - Asia 365
OC - Oceania 3
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 7.550
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.372
IT - Italia 351
CN - Cina 268
SE - Svezia 135
FI - Finlandia 113
GB - Regno Unito 71
DE - Germania 63
IN - India 43
VN - Vietnam 36
IE - Irlanda 20
FR - Francia 11
UA - Ucraina 11
NL - Olanda 7
TW - Taiwan 6
RS - Serbia 5
BE - Belgio 4
PL - Polonia 4
AU - Australia 3
CA - Canada 3
RU - Federazione Russa 3
SG - Singapore 3
TR - Turchia 3
CH - Svizzera 2
KR - Corea 2
AR - Argentina 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
GR - Grecia 1
HK - Hong Kong 1
HU - Ungheria 1
IR - Iran 1
JP - Giappone 1
LK - Sri Lanka 1
NO - Norvegia 1
Totale 7.550
Salva come PNG Salva come JPEG
Città #
Fairfield 1.274
Woodbridge 662
Chandler 632
Ashburn 558
Houston 476
Cambridge 412
Seattle 401
Wilmington 351
Ann Arbor 307
San Diego 181
Padova 125
Princeton 113
Medford 103
Helsinki 85
Roxbury 84
Beijing 82
Des Moines 79
New York 43
Dong Ket 36
Guangzhou 29
Nanjing 29
Boardman 26
London 19
Pune 19
Ogden 17
Venice 17
Nanchang 14
Arezzo 13
Columbus 13
Dublin 13
Milan 12
Washington 12
Jacksonville 11
Hounslow 9
Kharkiv 9
Rome 9
Jinan 8
Turin 8
Los Angeles 7
Paris 7
Shenyang 7
Cagliari 6
Lappeenranta 6
Pignone 6
Shanghai 6
Arzignano 5
Grumo Nevano 5
Gunzenhausen 5
Ningbo 5
Norwalk 5
Treviso 5
Vicenza 5
Acton 4
Changsha 4
Dearborn 4
Hangzhou 4
Hebei 4
Hsinchu County 4
Kilburn 4
Las Vegas 4
Tianjin 4
Amsterdam 3
Avezzano 3
Borås 3
Brussels 3
Chicago 3
Dongguan 3
Falls Church 3
Haikou 3
Jiaxing 3
Kunming 3
Limbiate 3
Mumbai 3
Redwood City 3
Samarate 3
Southwark 3
Winter Park 3
Albinea 2
Belluno 2
Bengaluru 2
Brisbane 2
Castagnole 2
Castelfranco Veneto 2
Cividale Del Friuli 2
Dallas 2
Duncan 2
Gdansk 2
Genoa 2
Goyang-si 2
Grisignano di Zocco 2
Grottaglie 2
Hefei 2
Lucca 2
Messina 2
Milazzo 2
Nanto 2
New Bedfont 2
New Delhi 2
Portland 2
Redmond 2
Totale 6.501
Salva come PNG Salva come JPEG
Nome #
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS) 163
A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib 151
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 143
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 138
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 131
Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections? 130
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal 125
Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience 124
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time 122
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 118
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 118
Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature 117
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 114
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 113
Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature 111
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 111
COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. 111
Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment 109
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists 108
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. 108
Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab 105
LKB1 and tumor metabolism: The interplay of immune and angiogenic microenvironment in lung cancer 105
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC) 101
Metabolic rewiring and redox alterations in malignant pleural mesothelioma 95
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial 94
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 93
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience 93
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data 87
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 86
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 82
Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection† 81
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy 81
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model 81
Effects of sulfonylureas on tumor growth: A review of the literature 78
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 78
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 78
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment 76
DNA copy number alterations correlate with survival in esophageal adenocarcinoma patients. 76
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 76
Synergistic antitumor activity of recombinant human Apo2L/Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma 76
Results of surgical resection after induction chemoradiation for Pancoast tumours 75
Liquid biopsy in malignant pleural mesothelioma: State of the art, pitfalls, and perspectives 74
DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma 72
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer 72
Squamous cell carcinomas of the lung and of the head and neck: New insights on molecular characterization 72
Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection 72
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 72
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 68
Lobectomy with artery reconstruction and pneumonectomy for NSCLC: a propensity score weighting study 68
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? 66
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 64
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 63
Molecular targets in malignant pleural mesothelioma treatment 63
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 63
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology 62
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 62
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 60
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy 60
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report. 58
PET/CT And The Response To Immunotherapy In Lung Cancer 57
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 57
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 57
Diagnostic challenges in epithelioid pleural mesothelioma: Case series with support from electron microscopy 56
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 55
A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients 54
realpse patterns and tailored treatment strategies for malignant pleural mesothelioma recurrence after multimodality therapy 52
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 52
Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel) 52
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 50
Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). 50
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 48
Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall 47
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 47
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 47
Vascular involvement in thymic epithelial tumors: Surgical and oncological outcomes 47
Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma 47
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer 45
Second and third line treatment in non-small cell lung cancer 44
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. 42
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience 42
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study 42
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 42
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis 42
RESEARCH OF PREDICTIVE AND PROGNOSTIC TISSUE AND MOLECULAR MARKERS AND OF NEW THERAPEUTIC TARGETS IN MALIGNANT PLEURAL MESOTHELIOMA 41
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. 39
Proposta di PDTA della Rete Oncologica Veneta per i pazienti affetti da tumori Neuroendocrini 39
An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma 39
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer 38
Prognostic factors in elderly patients with malignant pleural mesothelioma: Results of a multicenter survey 38
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma 38
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study 37
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment 36
Second and third line treatment in advanced non-small cell lung cancer 35
Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice 35
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial 33
The rarest of rare thymic lesions: A 10-year surgical pathology experience 33
Immune checkpoint inhibitors in mesothelioma: a turning point 32
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma 30
SMO mutations confer poor prognosis in malignant pleural mesothelioma 30
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 30
Totale 7.230
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.907
article - articoli 33.286
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 244
Totale 67.437
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019222 0 0 0 0 0 0 0 0 0 0 119 103
2019/20201.132 88 38 38 235 105 64 89 117 136 90 86 46
2020/20211.795 54 80 68 36 34 142 513 183 209 184 99 193
2021/20222.021 118 223 192 59 166 281 228 90 142 75 118 329
2022/20231.256 215 164 48 169 147 151 16 76 160 23 74 13
2023/2024859 42 109 113 97 68 166 75 65 70 52 2 0
Totale 7.767